Company / Cost of Revenue
UroGen Pharma Ltd. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$12.4M
FY2025
5-year range
$5.2M / $12.4M
FY2021-FY2025
Trend
+33.0%
vs FY2024
Sector context
#70 of 85
Health Care
What the data says
UroGen Pharma Ltd.'s cost of revenue of $12M is lower than 82% of companies in the Health Care sector (FY2025). Cost of Revenue has increased for 3 consecutive years, from $5M in FY2022 to $12M in FY2025.
Based on SEC 10-K filings.
$12M in FY2025 with a 5-year CAGR of +65.3%.
Increased from $8M to $12M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +34.1%
- 5-Year CAGR
- +65.3%
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 85This company $12.4M Sector average $2.0B
▼
-99.4% below sector average
Key checks
Key Insights
- UroGen Pharma Ltd.'s cost of revenue has grown for 3 consecutive years.
- 5-year CAGR of +65.3%, indicating consistent growth.
- In FY2025, cost of revenue increased 33.0% year-over-year.
- Ranks #70 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.4M | +33.0% |
| FY2024 | $9.4M | +22.3% |
| FY2023 | $7.7M | +48.4% |
| FY2022 | $5.2M | +0.0% |
| FY2021 | $5.2M | +411.1% |
| FY2020 | $1.0M | +68.2% |
| FY2019 | $600.0K | -66.7% |
| FY2018 | $1.8M | +200.5% |
| FY2017 | $600.0K | +2042.9% |
| FY2016 | $28.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026